Catégories
Insurance for Pets

Nestlé: Acquisition of Aimmune Therapeutics – Equity Research (Independent Research) | Stocks of the day – Insurance for Pets


Frankfurt (www.aktiencheck.de) – Nestlé stock analysis by analyst Lars Lusebrink from Independent Research:

Lars Lusebrink, an analyst at Independent Research, confirms his investment rating for the shares of the food company Nestlé S.A. in a current stock analysis. (ISIN: CH0038863350, WKN: A0Q4DC, ticker symbol: NESR, SIX Swiss Ex: NESN, Nasdaq OTC symbol: NSRGF).

Nestlé has signed a definitive agreement to take over Aimmune Therapeutics, in which the Swiss food company already holds around 25.6%. The biotech company Aimmune (product sales in the first half of 2020: USD 0.6 million) develops and markets therapies for the treatment of life-threatening food allergies. Aimmune’s drug Palforzia was the first and so far only drug to receive FDA approval in late January 2020 for the treatment of peanut allergies, including anaphylaxis, in children aged 4 to 17 years.

Nestlé is offering $ 34.50 per Aimmune share in cash, which is a high premium of 174% compared to the closing price on 08/28. (USD 12.60), but only around 10% above the Aimmune share price when Palforzia was approved (January 31). The purchase price for the outstanding 74.4% amounts to around USD 2.1 billion, which is to be financed through existing liquid funds (as of June 30, 2020: CHF 3.5 billion).

Nestlé manager Behar sees blockbuster potential at Palforzia in five to six years (annual sales:> USD 1 billion; Bloomberg consensus 2025: USD 906 million). The transaction, which is expected to be completed by the end of 2020, should make a positive contribution to earnings from 2022/2023. Lusebrink considers the complete takeover to be plausible and strategically sensible in view of the high sales potential of Palforzia, the favorable time (significant price decline since market approval) and the strengthening of the Nestlé Health Science portfolio.

Lars Lusebrink, an analyst at Independent Research, confirms his hold recommendation for Nestlé shares. The price target will remain at CHF 115. (Analysis from 02.09.2020)

Please also note the information on the disclosure obligation in the event of conflicts of interest within the meaning of Directive 2014/57 / EU and corresponding EU regulations for the aforementioned analyst company under the following link.

Stock exchanges Nestlé share:

L&S share price Nestlé share:
101.24 EUR + 1.42% (September 2nd, 2020, 10:21 am)

SIX Swiss Exchange share price Nestlé share:
109.76 CHF + 1.03% (September 2nd, 2020, 10:06 am)

ISIN Nestlé share:
CH0038863350

WKN Nestlé share:
A0Q4DC

Ticker symbol Nestlé share:
NESR

SIX Swiss Exchange ticker symbol Nestlé share:
NESN

Nasdaq OTC ticker symbol Nestlé share:
NSRGF

Brief profile of Nestlé S.A .:

Nestlé (ISIN: CH0038863350, WKN: A0Q4DC, ticker symbol: NESR, SIX Swiss Ex: NESN, Nasdaq OTC symbol: NSRGF) is the largest food manufacturer in the world and the recognized number one in nutrition, health and wellbeing. Nestlé products are available all over the world. In addition to frozen products, various beverages (coffee, tea, mineral water, etc.), dairy products and confectionery, pharmaceutical products, special foods and products for pets are also manufactured. The group’s best-known brands include Nescafé, Nesquik, Maggi, Thomy, KitKat, Buitoni, LC1, Smarties and many more.

With the acquisition of Pfizer’s baby food division in 2012, the group is also active in this area. In addition, Nestlé tests the health benefits of its products in the field of sports nutrition in the company’s own high-tech center in Lausanne. Here Nestlé Health Science is working on the development of special foods that are supposed to help with diabetes, cardiovascular problems and Alzheimer’s. The company has manufacturing facilities all over the world. (02.09.2020 / ac / a / a)

Disclosure of possible conflicts of interest:

You can view possible conflicts of interest on the site of the creator / source of the analysis.